Background: neovascular glaucoma (NVG) is a severe condition resulting from ischemia caused by conditions such as central retinal vein occlusion (CRVO), diabetic retinopathy (DR) and chronic uveitis. In NVG, there is neovascularization of the iris (NVI) and anterior chamber angle (NVA) mediated by vascular endothelial growth factor (VEGF) leads to elevation in the intraocular pressure (IOP). Intracameral injection of Bevacizumab show good result in regression of iris neovascularization. Objective: it was to determine the effect of intracameral injection of bevacizumab on the neo-vessels over the iris, and on the IOP in patients with NVG. Patients and Methods: this research is a comparative, prospective, non-randomized study. Fifteen patients of neovascular glaucoma (NVG) (≥21mmHg) (with rubeosis iridis) were divided into four groups. Group 1 had peripupillary vessel dilatations, group 2 had early neovascularization mainly in the chamber angle plus to peripupillary vessel dilatations, group 3 had prominent rubeosis with/without neovascular glaucoma, group 4 had most advanced rubeosis and injected with a single intracamerlar bevacizumab (0.05 ml at the limbus in the upper temporal quadrant) at Al-Azhar University hospital between March 2017-March 2018. Results: after six months of following up the 15 patients, only group 1 showed complete regression of iris neovascularization; group 2, group 3 showed partial regression at first but finally there was recurrence of iris neovascularization; and group 4 didnot show response at all to the treatment. Conclusion: regression of iris neovascularization was inversely proportional to the pre-injection grade. Lower grades were associated with a better response.